Introduction
Asthma is a common chronic disease that generally responds well to inhaled corticosteroids (ICS) and longacting β 2 agonists (LABA). National implementation of this approach, together with effective self-management education 1 terminated the epidemic of asthma deaths that plagued Australia and New Zealand in the 1980s. However, these improvements have now stalled, and asthma mortality may be rising again. Recent investigations into asthma deaths, both at a national level 2 or by Coronial Inquest reach similar conclusions, namely that there is a need to address asthma self-management skills, and to develop and implement innovative treatment strategies. Both of these responses are now within the scope of practice for health professionals who care for patients with asthma. In this clinical perspective, we will detail the assessment and management of a person with severe asthma.
What is severe asthma?
Severe asthma is defined as asthma which requires maximum controller therapy to prevent a patient from becoming uncontrolled, or which, despite high dose therapy, remains uncontrolled. 3 While severe asthma affects 3-5% of the population, 4 it is overrepresented in healthcare settings because it causes frequent exacerbations and consumes up to 50% of asthma-related healthcare costs. 5 The 'typical' profile of a person with severe asthma is someone aged 35-60 years who is highly symptomatic from their disease, has several comorbidities, such as mood disorder, obesity and cardiac disease, 6 and who has complications of their disease (e.g. reduced lung function) or its treatment. 7 Several 'red flags' that can prompt a physician to consider a diagnosis of severe asthma, or whether an individual is at risk of a severe attack are listed in Table 1 . Each of these features presents an opportunity for intervention to manage effectively the person with severe asthma. This could be by optimising self-management skills and addressing risk factors, by treating comorbidities, or by implementing targeted therapy for the airway components of severe asthma 10 ( Fig. 1 ).
An approach to severe asthma
Systematic assessment of severe asthma covers several domains ( Fig. 1 , Table 1 ) and leads to improved outcomes, 11 and is a prerequisite for access to targeted therapies. 6 The diagnosis of asthma is confirmed by objective demonstration of variable expiratory airflow obstruction using change in forced expiratory volume in 1 s (FEV 1 ), either spontaneously over time, before and after bronchodilator, or in response to a bronchial provocation agent (when baseline FEV 1 is normal). This is necessary because in some patients symptoms that can mimic asthma can be due to other conditions, such as vocal cord dysfunction (VCD) or bronchiectasis. However, it is noted that some patients with severe refractory asthma (SRA) may have minimal reversibility. Evidence of a past history of bronchodilator response or airway hyperresponsiveness can help in these situations.
It is also necessary to determine that asthma treatment is optimal, either as high dose ICS and a long-acting bronchodilator, or moderate dose ICS and two or more 
Why is asthma severe and refractory?
The next step is to ask why. Why is this person's asthma severe and refractory to treatment? Do they have optimal self-management skills? ( Table 2) . People need a minimum set of skills to manage their disease adequately. There has been a significant increase in the number of available inhaler devices in the market. This is driven by advances in chronic obstructive pulmonary disease (COPD) treatment, but creates problems, such as inhaler device polypharmacy and inhaler class duplication, which is a co-treatment with more than one drug from the same drug class. Assessment and correction of inhaler device technique can lead to improved asthma control. Unfortunately, poor technique is common. A systematic review of errors in inhaler technique has demonstrated that overall, the prevalence of optimal inhaler technique was only 31%, and that this had not improved in the last 40 years. 12 These data highlight the importance of basic asthma education in the management of asthma and severe disease. Inhaler device technique should be reviewed and corrected on a regular basis. The Lung Foundation of Australia and the National Asthma Council have both developed an inhaler device decoder and it is useful to have this accessible during a consultation (http://lungfoundation.com.au/ wp-content/uploads/2014/02/COPD-Medicines-WallChart_A4.pdf and https://assets.nationalasthma.org.au/ resources/58-Asthma-Medication-Chart-2015.pdf).
Treatment adherence is an important component of asthma self management. In severe asthma, nonadherence is a particularly critical issue, as it has been reported in 32-56% of patients, and is associated with poor outcomes, including exacerbation and mortality. 3 To assess adherence surrogate markers, such as medication Management of severe asthma prescription refills, inhaler device counters and weighing of inhalers are more reliable than subjective questioning, that is, asking the patient; however, these methods are not infallible and are not easily integrated into clinical practice. 13 More novel techniques for assessing adherence, such as a fraction exhaled nitric oxide suppression test after directly observed ICS therapy are also gaining interest in research and clinical settings.
14 However, in practice, often the only technique available to clinicians is direct questioning and/or questionnaire, normalising nonadherence gives patients the permission to respond more openly about their medication use; an example of this is 'Sometimes it is difficult to remember your medication, how many doses have you forgotten in the last week?' Strategies to improve adherence to medication include an identification of the type of and reason for the behaviour, with tailoring of interventions to these reasons. Simplification of medication regimen, goal setting, telephone support, diary monitoring with feedback and shared decision making are strategies that have been effective in asthma. 15 
Have trigger factors been identified and managed?
Allergic and non-allergic factors play a role in inducing asthma, as well as exacerbating symptoms and airway inflammation. Cockroach allergen and the fungi Alternaria tenuiis and Aspergillus fumigatus are associated with more severe disease and exacerbations. 16 Occupational exposures can also be relevant (http://www. severeasthma.org.au/tools-resources/past-webinars/).
Identifying triggers in each individual and implementing appropriate management strategies are necessary, as this can lead to improved control. In many cases, avoidance or minimising exposure is the recommended approach; however, this is not always possible so alternative strategies should be implemented. Table 3 details the most common triggers associated with asthma, as well as identification strategies and recommended management approaches.
What is the pattern of airway inflammation?
A patient with confirmed asthma, who has persistent symptoms, exacerbations and/or airflow obstruction despite optimisation of risk factors and comorbidity, has SRA. These patients can undergo inflammatory phenotyping to identify the endogenous mechanistic pathway, or endotype, that may be driving their disease. Recognised inflammatory endotypes are eosinophilic, allergic and non-eosinophilic asthma (Fig. 2) . Targeted treatment is now available for patients with SRA and an allergic or eosinophilic endotype.
Severe refractory allergic asthma (SRAA)
Omalizumab (OMA) is a humanised IgG1kappa monoclonal antibody that binds to free immunoglobulin E (IgE). This prevents binding of IgE to high affinity IgE receptors on mast cells and basophils, and to low-affinity IgE receptors on eosinophils and T lymphocytes. This The drug is administered in a healthcare setting through subcutaneous injection each 2-4 weeks using a prefilled syringe. The dose is determined by baseline IgE level and bodyweight. The most significant adverse effect is anaphylaxis, with rates of one to two patients per 1000. Other clinically recognised adverse effects include headaches with migraine-like qualities and injection site reactions. Post-marketing surveillance through the Australian Xolair Registry has confirmed the efficacy and safety of OMA in the Australian setting, and in SRAA patients with high prevalence of comorbid disease, a population often excluded from clinical trials. 6 Clinically eligible patients have SRAA with serum IgE >30 IU/L and positive specific IgE to an allergen.
Severe refractory eosinophilic asthma (SREA)
Severe refractory eosinophilic asthma causes frequent exacerbations, poor asthma control and impaired quality of life. The haemopoietic cytokine interleukin (IL)-5 controls the growth, differentiation and activation of eosinophils and is a target of treatment in SREA. The major cellular sources of IL-5 in asthma are Th2 cells, mast cells, group 2 innate lymphoid cells and eosinophils themselves. Approved treatment options for SREA are maintenance oral corticosteroids (OCS) and mepolizumab, an anti-IL5 monoclonal antibody. OCS are effective, but cause significant toxicity. 7 Monoclonal antibodies directed against IL-5 (mepolizumab, reslizumab), or its receptor (benralizumab) have been developed to treat SREA. 18 Mepolizumab is a humanised IgG1kappa monoclonal antibody that binds to and neutralises IL-5, leading to a reduction in circulating and airway eosinophils. Mepolizumab is reconstituted immediately before administration by subcutaneous injection, in a healthcare setting at monthly intervals. The drug is approved for use in Australia through the Therapeutic Goods Administration. In several clinical trials, mepolizumab led to a highly significant reduction in asthma exacerbations. In a meta-analysis, the relative rate for hospitalisations compared to placebo was 0.49; 95% confidence interval (CI), 0.30-0.80; P = 0.004 and for hospitalisation/emergency room visit, the relative rate was 0.49; 95% CI, 0.33-0.73; P < 0.001). 19 It also has an oral-steroid sparing effect, permitting an average OCS dose reduction of 50% in patients with severe OCS-dependent eosinophilic asthma. 18 Responding patients are adults and adolescents with severe asthma, who experience persistent asthma exacerbations despite optimal inhaled therapy, and with evidence of eosinophilia from blood eosinophil counts (>0.3 × 10E9/l) or sputum eosinophilia (>3%). While this level of blood eosinophils is within the normal range, it should be noted that the persistence of circulating eosinophils is a marker for eosinophilic airway disease in these patients. This is because the quoted normal range for blood eosinophils has been calculated, including atopic individuals, and studies that exclude people with atopic disorders find a lower level for the upper normal range. The persistence of even low levels of blood eosinophils may be abnormal in corticosteroidtreated patients, and is consistent with observations that values of 0.3 × 10E9/L are associated with airway eosinophilia in corticosteroid-treated asthma. 20 Targeted therapy for non-eosinophilic asthma is not yet available. Potential options include high dose longacting bronchodilators (LABA), or low dose macrolide antibiotics, both of which can reduce airway neutrophils. It is considered that non-eosinophilic asthma may represent several different endotypes, and research is needed to define these endotypes and test specific therapies.
Pulmonary comorbidity
A number of lung diseases can occur either in association with, or as a consequence of severe asthma (Table 4) . Incompletely reversible airflow obstruction (COPD) is common in SRA. It is recognised by reduced FEV 1 and treated by LABD. Dual LABD, that is, long-acting muscarinic antagonists, added to LABA, is effective for this problem in severe asthma.
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Bronchiectasis
High-resolution computed tomography scanning of the thorax identifies bronchiectasis in 35-40% of patients with severe asthma. In some cases, it is associated with sensitisation to the ubiquitous fungus Aspergillus fumigatus. Clinical manifestations of this include allergic bronchopulmonary aspergillosis (ABPA) (see below), airway mucus hypersecretion and airway dysbiosis.
ABPA
ABPA and severe asthma with fungal sensitisation are phenotypes of fungal-sensitised asthma. ABPA is diagnosed based on a constellation of symptoms, elevated serum total IgE >1000 IU/mL, sensitisation to A. fumigatus and X-ray abnormalities. It is usually also associated with colonisation of Aspergillus in the airway. Fungal sensitisation is an important problem in severe asthma. Effective treatment of APBA may include itraconazole.
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Extra-pulmonary comorbidity and severe asthma
Comorbid disease is common in severe asthma. Identification and treatment of comorbidity can improve a patient's quality of life and in some cases may improve respiratory symptoms. This is explained by symptom misattribution or a link between the comorbid disease and asthma. There is a prevalent cluster of upper airway comorbid disease in severe asthma. These include rhinosinusitis, obstructive sleep apnoea, VCD and gastroesophageal reflux disease with proximal regurgitation. Other relevant comorbidities include dysfunctional breathing, obesity and anxiety and depression. These conditions can be assessed by history or the use of validated questionnaires, with evidence-based guidelines used to guide objective testing and treatment (Table 5) .
Vocal cord dysfunction
Paradoxical inspiratory closure of the vocal cords can cause symptoms that mimic asthma. 23 As this problem does not respond to asthma therapy, a patient with VCD may present as having severe and refractory symptoms. The condition has many names, the most commonly used current labels are VCD or paradoxical vocal fold movement (PVFM). A recent task force has proposed a new name, inducible laryngeal obstruction (ILO). VCD/PVFM/ILO is a disorder of laryngeal function where laryngeal structure is normal. It is recognised by typical symptoms of dyspnoea, dysphonia, symptoms triggered by scents/odours/phonation and non-response to inhaled β2 agonists. A questionnaire can facilitate recognition. Objective confirmation of the diagnosis is achieved by visualisation of the larynx either at nasendoscopy, by dynamic computed tomography scan of the neck 24 ( Fig. 3) , or abnormal inspiratory flow volume-curves that demonstrate variable extrathoracic airflow obstruction. VCD/PVFM/ILO can respond to multi-modal speech pathology intervention. Recognition and treatment of VCD can improve symptoms in a patient with VCD alone (mimicking severe asthma) or in a patient with both severe asthma and VCD. VCD is under-diagnosed and under-treated in patients who present for assessment of severe asthma.
Dysfunctional breathing
Dysfunctional breathing or hyperventilation syndrome is recognised as common problems in asthma, with a prevalence of around 35%. The term describes a group of conditions that involve chronic changes in breathing patterns that result in breathlessness, and where the symptoms occur in the absence of, or in excess of, an organic respiratory condition. 25 While there is no gold standard diagnostic tool, the Nijmegen questionnaire is a validated simple 16-item self-administered screening tool that is useful for identification. Teaching patients breathing retaining techniques, such as the Papworth method can assist in symptom control. 25 Identification and treatment of dysfunctional breathing in asthma are particularly important in order to ameliorate anxiety related to excessive symptoms and to avoid over medicating with asthma treatment in the case of symptom misattribution.
Obesity
The prevalence of obesity in severe asthma is high. In an Australian severe asthma disease register, 45% of participants with SRAA had a body mass index >30 kg/m 2 .
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Obesity has deleterious consequences and potentiates multiple and connected comorbidities, including cardiovascular disease, metabolic syndrome and type 2 diabetes. In asthma, obesity has additional impacts. It increases the likelihood of asthma and increases disease severity and the symptom burden. Targeting weight loss in patients with obese asthma is of paramount importance, and achieving a loss of as low as 5-10% of bodyweight leads to significant improvements in asthma control and health status. Weight loss strategies involving nutritional counselling and a very low calorie diet (meal replacement therapies) and in combination with exercise are effective.
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Anxiety and depression
Psychological morbidity is common in patients with airway diseases, such as COPD and severe asthma, but it is often under-diagnosed and under-treated. In an evaluation of patients referred to a severe asthma clinic in Melbourne, over 30% scored greater than 11 on the depression or anxiety domain of the hospital anxiety and depression scale, indicating probable anxiety or depression. 27 This psychological morbidity can lead to increasing symptoms, treatment non-adherence and social isolation, and can increase the risk for severe exacerbations. There are several screening tools that can be used in the clinic to help identify patients who may be suffering from anxiety and depression, and may require treatment. In severe asthma itself, there are very few if any treatment intervention studies reported for the management of anxiety and depression, and the need for new knowledge in this area is great.
Conclusion
Management of asthma has improved significantly over the past three decades, and advances in pharmacotherapy and asthma self-management education strategies have been drivers of these improvements. Severe asthma however remains a major problem, with asthma deaths in Australia high by international standards. Severe asthma is a heterogeneous disease and treatments must target the array of characteristics that are present in individuals. These characteristics include the patho-biological traits of the airway, but importantly move beyond this disease centric approach and must include careful assessment of and attention to risk factors related to severe asthma and related comorbidities. Multidimensional assessment and individualised management that is targeted to these components are necessary to achieve the best outcomes in this complex disease. In this article, we have presented an overview of severe asthma and propose practical approaches for management of the disease and its components.
